SKIN Relative Valuation
SKIN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SKIN is overvalued; if below, it's undervalued.
Historical Valuation
Beauty Health Co (SKIN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 48.21. The fair price of Beauty Health Co (SKIN) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.58 USD , Beauty Health Co is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.58
Fair
Undervalued
10.36
PE
1Y
3Y
5Y
Trailing
Forward
10.28
EV/EBITDA
Beauty Health Co. (SKIN) has a current EV/EBITDA of 10.28. The 5-year average EV/EBITDA is 36.67. The thresholds are as follows: Strongly Undervalued below -52.92, Undervalued between -52.92 and -8.12, Fairly Valued between 81.46 and -8.12, Overvalued between 81.46 and 126.25, and Strongly Overvalued above 126.25. The current Forward EV/EBITDA of 10.28 falls within the Historic Trend Line -Fairly Valued range.
-43.79
EV/EBIT
Beauty Health Co. (SKIN) has a current EV/EBIT of -43.79. The 5-year average EV/EBIT is 83.98. The thresholds are as follows: Strongly Undervalued below -529.82, Undervalued between -529.82 and -222.92, Fairly Valued between 390.88 and -222.92, Overvalued between 390.88 and 697.78, and Strongly Overvalued above 697.78. The current Forward EV/EBIT of -43.79 falls within the Historic Trend Line -Fairly Valued range.
0.68
PS
Beauty Health Co. (SKIN) has a current PS of 0.68. The 5-year average PS is 3.53. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and -0.09, Fairly Valued between 7.15 and -0.09, Overvalued between 7.15 and 10.77, and Strongly Overvalued above 10.77. The current Forward PS of 0.68 falls within the Historic Trend Line -Fairly Valued range.
7.43
P/OCF
Beauty Health Co. (SKIN) has a current P/OCF of 7.43. The 5-year average P/OCF is 27.78. The thresholds are as follows: Strongly Undervalued below -103.36, Undervalued between -103.36 and -37.79, Fairly Valued between 93.34 and -37.79, Overvalued between 93.34 and 158.91, and Strongly Overvalued above 158.91. The current Forward P/OCF of 7.43 falls within the Historic Trend Line -Fairly Valued range.
25.18
P/FCF
Beauty Health Co. (SKIN) has a current P/FCF of 25.18. The 5-year average P/FCF is -259.62. The thresholds are as follows: Strongly Undervalued below -2513.72, Undervalued between -2513.72 and -1386.67, Fairly Valued between 867.43 and -1386.67, Overvalued between 867.43 and 1994.48, and Strongly Overvalued above 1994.48. The current Forward P/FCF of 25.18 falls within the Historic Trend Line -Fairly Valued range.
Beauty Health Co (SKIN) has a current Price-to-Book (P/B) ratio of 3.06. Compared to its 3-year average P/B ratio of 5.18 , the current P/B ratio is approximately -40.92% higher. Relative to its 5-year average P/B ratio of 11.81, the current P/B ratio is about -74.05% higher. Beauty Health Co (SKIN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.07%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.38% , the current FCF yield is about -100.00% lower.
3.06
P/B
Median3y
5.18
Median5y
11.81
19.00
FCF Yield
Median3y
2.07
Median5y
0.38
Competitors Valuation Multiple
The average P/S ratio for SKIN's competitors is 6.32, providing a benchmark for relative valuation. Beauty Health Co Corp (SKIN) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -10.34%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SKIN decreased by 0.63% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -6.23 to -8.88.
The secondary factor is the Revenue Growth, contributed -10.34%to the performance.
Overall, the performance of SKIN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Beauty Health Co (SKIN) currently overvalued or undervalued?
What is Beauty Health Co (SKIN) fair value?
How does SKIN's valuation metrics compare to the industry average?
What is the current P/B ratio for Beauty Health Co (SKIN) as of Dec 05 2025?
What is the current FCF Yield for Beauty Health Co (SKIN) as of Dec 05 2025?
What is the current Forward P/E ratio for Beauty Health Co (SKIN) as of Dec 05 2025?